The American Cancer Society’s Cancer Statistics, 2026 report highlights a historic milestone: the 5-year relative survival ...

Carfilzomib prevented BCMA degradation, increased target density, and improved CAR T susceptibility by ~26%–28% in vitro, while enhancing xenograft antitumor activity without worsening T-cell ...

IDH -mutant gliomas represent a rare subset of brain tumors, affecting approximately 12% to 20% of adult patients with glioma ...

Minimal residual disease (MRD) refers to the small number of myeloma cells that may remain after treatment and are not detectable using conventional response criteria. In multiple myeloma, MRD ...

An ongoing phase 2 trial (NCT07222579) has seen early success with a new subcutaneous formulation of blinatumomab (Blincyto) in a patient with CD19-positive mixed phenotype acute leukemia (MPAL), a ...

Precision oncology represents a fundamental shift in how we treat malignancy. Rather than the broad-spectrum "carpet bombing" of traditional chemotherapy, the field focuses on "identifying a gene, a ...

The study concludes that at-home self-sampling is a "people-centered" approach that can reduce the burden on strained ...

For 3 decades, the clinical narrative for limited-stage small cell lung cancer (LS-SCLC) was one of grim consistency. Patients diagnosed with this aggressive neuroendocrine malignancy—a disease ...

In this concluding segment, Dr Shaheen focuses on how shared decision making and quality of life considerations guide treatment selection in later line pancreatic neuroendocrine tumor care. She ...

The FDA granted breakthrough therapy designation to Rybrevant Faspro based on data from the phase 1b/2 OrigAMI-4 study (NCT06385080).

The 5-mg dose of oxybutynin reduced the frequency and severity of hot flashes in men with prostate cancer undergoing treatment with androgen-deprivation therapy compared with placebo.

How HRD and BRCA results steer frontline ovarian cancer maintenance—niraparib vs olaparib—plus guidance on recurrence, ...